Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years

被引:5
|
作者
Gotfredsen, Ditte Resendal [1 ]
Vinther, Siri [1 ]
Petersen, Tonny Studsgaard [1 ,2 ]
Cortes, Rikke [1 ]
Jensen, Thomas Bo [1 ,2 ]
Jimenez-Solem, Espen [1 ,2 ]
Christensen, Mikkel Bring [1 ,2 ,3 ]
机构
[1] Bispebjerg & Frederiksberg Hosp, Dept Clin Pharmacol, Copenhagen, Denmark
[2] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[3] Univ Copenhagen, Gentofte Hosp, Ctr Clin Metab Res, Hellerup, Denmark
关键词
OLDER-ADULTS; SEVERE HYPOGLYCEMIA; POTENTIAL OVERTREATMENT; MELLITUS; TRENDS; PEOPLE; ASSOCIATION; PREVALENCE; GUIDELINES; EVENTS;
D O I
10.1038/s41598-020-60818-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Treatment guidelines for type 2 diabetes (T2D) recommend avoidance of hypoglycemia and less stringent glycemic control in older patients. We examined the relation of glycemic control to glucose-lowering medications use in a cohort of patients aged>80 years with a diagnosis of T2D and a hospital admission in the Capital Region of Denmark in 2012-2016. We extracted data on medication use, diagnoses, and biochemistry from the hospitals' records. We identified 5,172 T2D patients with high degree of co-morbidity and where 17% had an HbA(1c) in the range recommended for frail, comorbid, older patients with type 2 diabetes (58-75 mmol/mol (7.5-9%)). Half of the patients (n = 2,575) had an HbA1c <48 mmol/mol (<6.5%), and a majority of these (36% of all patients) did not meet the diagnostic criteria for T2D. Of patients treated with one or more glucose-lowering medications (n = 1,758), 20% had HbA(1c)-values <42 mmol/mol (<6%), and 1% had critically low Hba(1c) values <30 mmol/mol (<4.9%), In conclusion, among these hospitalized T2D patients, few had an HbA(1c) within the generally recommended glycemic targets. One third of patients did not meet the diagnostic criteria for T2D, and of the patients who were treated with glucose-lowering medications, one-fifth had HbA(1c)-values suggesting overtreatment.
引用
收藏
页数:8
相关论文
共 50 条
  • [11] Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?
    Ahren, Bo
    DIABETOLOGIA, 2015, 58 (08) : 1740 - 1744
  • [12] Influence of Supervised Disease Understanding and Diabetes Self-Management on Adherence to Oral Glucose-Lowering Treatment in Patients with Type 2 Diabetes
    Doupis, John
    Alexandrides, Theodoros
    Elisaf, Moses
    Melidonis, Andreas
    Bousboulas, Stavros
    Thanopoulou, Anastasia
    Pagkalos, Emmanouil M.
    Avramidis, Iakovos
    Pappas, Angelos
    Arvaniti, Eleni
    Karamousouli, Eugenia
    Voss, Bernd
    Tentolouris, Nikolaos
    DIABETES THERAPY, 2019, 10 (04) : 1407 - 1422
  • [13] Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR)
    Arnold, Suzanne V.
    Echouffo-Tcheugui, Justin B.
    Lam, Carolyn S. P.
    Inzucchi, Silvio E.
    Tang, Fengming
    McGuire, Darren K.
    Goyal, Abhinav
    Maddox, Thomas M.
    Sperling, Laurence S.
    Fonarow, Gregg C.
    Masoudi, Frederick A.
    Kosiborod, Mikhail
    AMERICAN HEART JOURNAL, 2018, 203 : 25 - 29
  • [14] The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes
    Vissers, Pauline A. J.
    Cardwell, Chris R.
    van de Poll-Franse, Lonneke V.
    Young, Ian S.
    Pouwer, Frans
    Murray, Liam J.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 150 (02) : 427 - 437
  • [15] Chronic Medication Burden and Complexity for US Patients with Type 2 Diabetes Treated with Glucose-Lowering Agents
    Boye, Kristina S.
    Mody, Reema
    Lage, Maureen J.
    Douglas, Steven
    Patel, Hiren
    DIABETES THERAPY, 2020, 11 (07) : 1513 - 1525
  • [16] Seasonal Variation in Severe Glucose-lowering Drug-induced Hypoglycemia in Patients with Type 2 Diabetes
    Minamoto-Higashioka, Mayu
    Kawamura, Ryoichi
    Umakoshi, Hironobu
    Yokomoto-Umakoshi, Maki
    Utsunomiya, Daisuke
    Osawa, Haruhiko
    Kondo, Shiori
    INTERNAL MEDICINE, 2019, 58 (08) : 1067 - 1072
  • [17] A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes
    Javier Ampudia-Blasco, F.
    Benhamou, Pierre Yves
    Charpentier, Guillaume
    Consoli, Agostino
    Diamant, Michaela
    Gallwitz, Baptist
    Khunti, Kamlesh
    Mathieu, Chantal
    Ridderstrale, Martin
    Seufert, Jochen
    Tack, Cees
    Vilsboll, Tina
    Tra-Mi Phan
    Stoevelaar, Herman
    DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 (03) : 194 - 202
  • [18] Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care
    O'Hara, Daniel, V
    Janse, Roemer J.
    Fu, Edouard L.
    Jardine, Meg J.
    Carrero, Juan-Jesus
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 213
  • [19] Network meta-analysis of glucose-lowering drug treatment regimens with the potential risk of hypoglycemia in patients with type 2 diabetes mellitus in terms of glycemic control and severe hypoglycemia
    Kodama, Satoru
    Fujihara, Kazuya
    Ishiguro, Hajime
    Matsubayashi, Yasuhiro
    Kitazawa, Masaru
    Iwanaga, Midori
    Yamada, Takaho
    Kato, Kiminori
    Nakagawa, Yoshimi
    Tanaka, Shiro
    Shimano, Hitoshi
    Sone, Hirohito
    JOURNAL OF INVESTIGATIVE MEDICINE, 2023, 71 (04) : 400 - 410
  • [20] The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
    Currie, C. J.
    Poole, C. D.
    Gale, E. A. M.
    DIABETOLOGIA, 2009, 52 (09) : 1766 - 1777